Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study
Standard
Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. / Sinn, Marianne; Striefler, Jana K; Sinn, Bruno V; Sallmon, Daniel; Bischoff, Sven; Stieler, Jens M; Pelzer, Uwe; Bahra, Marcus; Neuhaus, Peter; Dörken, Bernd; Denkert, Carsten; Riess, Hanno; Oettle, Helmut.
in: J SURG ONCOL, Jahrgang 108, Nr. 6, 11.2013, S. 398-402.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study
AU - Sinn, Marianne
AU - Striefler, Jana K
AU - Sinn, Bruno V
AU - Sallmon, Daniel
AU - Bischoff, Sven
AU - Stieler, Jens M
AU - Pelzer, Uwe
AU - Bahra, Marcus
AU - Neuhaus, Peter
AU - Dörken, Bernd
AU - Denkert, Carsten
AU - Riess, Hanno
AU - Oettle, Helmut
N1 - © 2013 Wiley Periodicals, Inc.
PY - 2013/11
Y1 - 2013/11
N2 - BACKGROUND: Long-term survival (LTS) in patients (pts) with pancreatic cancer is still uncommon, little data is available to identify long-term survivors. The CONKO-001 study, which established gemcitabine after resection as adjuvant therapy, may provide data to answer this question.METHODS: CONKO-001 pts with an overall survival ≥5 years were compared to those who survived <5 years. Central re-evaluation of primary histology was performed. Univariate analysis with the χ(2) -test identified qualifying factors. Logistic regression was used to investigate the influence of these covariates on LTS.RESULTS: Of the evaluable 354 CONKO-001 pts, 54 (15%) with an overall survival ≥5 years were identified. It was possible to obtain tumor specimens of 39 pts (72%). Histological re-evaluation confirmed adenocarcinoma in 38 pts, 1 showed a high-grade neuroendocrine tumor. Univariate analysis for all 53 LTS pts with adenocarcinoma compared to the remaining 300 non-LTS pts revealed as relevant active treatment, tumor grading, tumor size, lymph nodes. No significance could be demonstrated for resection margin, sex, age, Karnofsky performance status, CA 19-9 at study entry. In multivariate analysis, tumor grading, active treatment, tumor size, lymph node involvement were independent prognostic factors for LTS.CONCLUSION: Long-term survival can be achieved in adenocarcinoma of the pancreas.
AB - BACKGROUND: Long-term survival (LTS) in patients (pts) with pancreatic cancer is still uncommon, little data is available to identify long-term survivors. The CONKO-001 study, which established gemcitabine after resection as adjuvant therapy, may provide data to answer this question.METHODS: CONKO-001 pts with an overall survival ≥5 years were compared to those who survived <5 years. Central re-evaluation of primary histology was performed. Univariate analysis with the χ(2) -test identified qualifying factors. Logistic regression was used to investigate the influence of these covariates on LTS.RESULTS: Of the evaluable 354 CONKO-001 pts, 54 (15%) with an overall survival ≥5 years were identified. It was possible to obtain tumor specimens of 39 pts (72%). Histological re-evaluation confirmed adenocarcinoma in 38 pts, 1 showed a high-grade neuroendocrine tumor. Univariate analysis for all 53 LTS pts with adenocarcinoma compared to the remaining 300 non-LTS pts revealed as relevant active treatment, tumor grading, tumor size, lymph nodes. No significance could be demonstrated for resection margin, sex, age, Karnofsky performance status, CA 19-9 at study entry. In multivariate analysis, tumor grading, active treatment, tumor size, lymph node involvement were independent prognostic factors for LTS.CONCLUSION: Long-term survival can be achieved in adenocarcinoma of the pancreas.
KW - Adenocarcinoma/drug therapy
KW - Aged
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Chemotherapy, Adjuvant
KW - Deoxycytidine/administration & dosage
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Kaplan-Meier Estimate
KW - Logistic Models
KW - Lymphatic Metastasis
KW - Male
KW - Middle Aged
KW - Multivariate Analysis
KW - Neoplasm Grading
KW - Neoplasm Staging
KW - Pancreatic Neoplasms/drug therapy
KW - Prognosis
KW - Risk Factors
KW - Time Factors
U2 - 10.1002/jso.23409
DO - 10.1002/jso.23409
M3 - SCORING: Journal article
C2 - 24038103
VL - 108
SP - 398
EP - 402
JO - J SURG ONCOL
JF - J SURG ONCOL
SN - 0022-4790
IS - 6
ER -